NR1H3 and metabolic syndrome: The evaluation of LXRα transcriptional activity showed that 88 and 89 were 3.16- and 2.62-fold activation of LXRα at a concentration of 100 μg/ml, indicating their potential utility against metabolic syndrome (Vásqueza et al., 2019).